Pierre‐François Laterre

22.6k citations

182 papers · 12.8k indexed · 3 hit papers · h-index 50

Epidemiology top 0.1%
Pulmonary and Respiratory Medicine top 0.5%
Critical Care and Intensive Care Medicine top 0.05%
Surgery top 1%
Immunology top 2%

Co-authors: Jean‐Louis Vincent Jean-François Dhainaut E. Wesley Ely Jeffrey D. Helterbrand Charles J. Fisher Xavier Wittebole Thierry Dugernier Howard Levy
Topics: Sepsis Diagnosis and Treatment (61 papers)Intensive Care Unit Cognitive Disorders (23 papers)Respiratory Support and Mechanisms (21 papers)
Cited by: Critical Care and Intensive Care Medicine Epidemiology Applied Microbiology and Biotechnology
Journals: New England Journal of MedicineSHILAP Revista de lepidopterologíaPLoS ONE
Partner nations: Belgium France United States

In The Last Decade

Pierre‐François Laterre

180 papers receiving 12.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis

2001 4.0k citations Jean‐Louis Vincent, Pierre‐François Laterre et al. New England Journal of Medicine profile →
Hydrocortisone Therapy for Patients with Septic Shock

2008 1.3k citations Pierre‐François Laterre, Konrad Reinhart et al. New England Journal of Medicine profile →
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death

2005 567 citations Edward Abraham, Pierre‐François Laterre et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Pierre‐François Laterre

Since Specialization

Citations

This map shows the geographic impact of Pierre‐François Laterre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre‐François Laterre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre‐François Laterre more than expected).

Fields of papers citing papers by Pierre‐François Laterre

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre‐François Laterre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre‐François Laterre. The network helps show where Pierre‐François Laterre may publish in the future.

Co-authorship network of co-authors of Pierre‐François Laterre

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre‐François Laterre. A scholar is included among the top collaborators of Pierre‐François Laterre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre‐François Laterre. Pierre‐François Laterre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pathogen-specific host response in critically ill patients with blood stream infections: a nested case–control study 2025 ·EBioMedicine ·Joe M. Butler,Hessel Peters‐Sengers,Tom D. Y. Reijnders,Tjitske S. R. van Engelen,Fabrice Uhel,Lonneke A. van Vught,Marcus J. Schultz,Pierre‐François Laterre,Bruno François,Miguel Sánchez García,Eleuterio Lombardo,Timothy E. Sweeney,Marc J. M. Bonten,(unknown),Dayle Sampson,(unknown),Thomas D. Yager,Olaf L. Cremer,Brendon P. Scicluna,Tom van der Poll	1
2	Population pharmacokinetics and dosing simulations of total and unbound temocillin in the plasma and CSF of neurocritically ill patients with external ventricular drain-related cerebral ventriculitis 2023 ·Journal of Antimicrobial Chemotherapy ·(unknown),Xin Liu,Suzanne L. Parker,Alexia Verroken,Christine Collienne,Patrice Finet,(unknown),Pierre‐François Laterre,Jason A. Roberts,Françoise Van Bambeke,Xavier Wittebole	1
3	NETosis and Nucleosome Biomarkers in Septic Shock and Critical COVID-19 Patients: An Observational Study 2022 ·Biomolecules ·Laure Morimont,Mélanie Dechamps,Clara David,Céline Bouvy,Constant Gillot,Hélène Haguet,Julien Favresse,(unknown),(unknown),Mariëlle Herzog,Pierre‐François Laterre,(unknown),Sandrine Horman,Christophe Beauloye,Jonathan Douxfils	24
4	Increased Angiotensin-Converting Enzyme 2 and Loss of Alveolar Type II Cells in COVID-19–related Acute Respiratory Distress Syndrome 2021 ·American Journal of Respiratory and Critical Care Medicine ·Ludovic Gérard,Marylène Lecocq,Caroline Bouzin,Delphine Hoton,G. Schmit,(unknown),Virginie Montiel,(unknown),Pierre‐François Laterre,Charles Pilette	48
5	Prise en charge des infections intra-abdominales 2015 ·Anesthésie & Réanimation ·Philippe Montravers,Hervé Dupont,Marc Léone,Jean Michel Constantin,Paul‐Michel Mertès,Pierre‐François Laterre,Benoît Misset,J.P. Bru,R. Gauzit,Albert Sotto,Cécile Brigand,A. Hamy,Jean‐Jacques Tuech	11
6	Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes 2014 ·Critical Care ·Qin Lü,Philippe Eggimann,Charles‐Édouard Luyt,Michel Wolff,Michael Tamm,Bruno François,Emmanuelle Mercier,Jorge Garbino,Pierre‐François Laterre,(unknown),Verena Gafner,Michael P. Rudolf,(unknown),(unknown),Hedvika Lazar,Jean Chastre,Jean‐Jacques Rouby	64
7	S100A12 and Soluble Receptor for Advanced Glycation End Products Levels During Human Severe Sepsis 2013 ·Shock ·Ahmed Achouiti,Dirk Föll,Thomas Vogl,J. W. Olivier van Till,Pierre‐François Laterre,Thierry Dugernier,Xavier Wittebole,Marja A. Boermeester,Johannes Roth,Tom van der Poll,Marieke A. D. van Zoelen	28
8	Alkaline Phosphatase Improves Kidney Function in Icu Patients With Sepsis-induced Acute Kidney Injury 2010 ·Intensive Care Medicine ·Peter Pickkers,Pierre‐François Laterre,Jeroen Schouten,Jean‐Louis Vincent,Johan Groeneveld,Philippe G. Jorens,Herbert Spapen,Suzanne Heemskerk,H. van der Hoeven	1
9	Drotrecogin alfa (activated) in severe sepsis - Reply 2006 ·New England Journal of Medicine ·Edward Abraham,Pierre‐François Laterre	3
10	Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study* 2005 ·Critical Care Medicine ·Pierre‐François Laterre,Gary Garber,Howard Levy,Richard G. Wunderink,Gary T. Kinasewitz,Jean-Pierre Sollet,Dennis G. Maki,Becky Bates,Sau Chi Betty Yan,Jean-François Dhainaut	132
11	The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis * 2004 ·Critical Care Medicine ·Derek C. Angus,Pierre‐François Laterre,(unknown),E. Wesley Ely,Daniel Ball,Rekha Garg,Lisa A. Weissfeld,Gordon R. Bernard	99
12	Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial* 2004 ·Critical Care Medicine ·Steven M. Opal,Pierre‐François Laterre,Edward Abraham,Bruno François,Xavier Wittebole,S. C. Lowry,Jean-François Dhainaut,Brian Warren,Thierry Dugernier,Ángel Crespo López,Miguel Sánchez,Ignace Demeyer,Luis Jáuregui,José A. Lorente,William T. McGee,Konrad Reinhart,(unknown),Sonia Souza,John P. Pribble	103
13	Sources of variability on the estimate of treatment effect in the PROWESS trial: Implications for the design and conduct of future studies in severe sepsis* 2004 ·Critical Care Medicine ·William L. Macias,B. Vallet,Gordon R. Bernard,Jean‐Louis Vincent,Pierre‐François Laterre,David R. Nelson,(unknown),Jean-François Dhainaut	38
14	Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis 2003 ·Critical Care Medicine ·E. Wesley Ely,Pierre‐François Laterre,Derek C. Angus,Jeffrey D. Helterbrand,Howard Levy,Jean-François Dhainaut,Jean‐Louis Vincent,William L. Macias,Gordon R. Bernard	192
15	Drotrecogin alfa (activated) in severe sepsis patients with 2 or more organ dysfunctions 2002 ·Intensive Care Medicine ·Jean François Dhainaut,Pierre‐François Laterre,Bruce R. Basson,(unknown)	4
16	The efficacy and safety of recombinant human activated protein C for the treatment of patients with severe sepsis (vol 28, pg 48, 2000) 2001 ·Critical Care Medicine ·GR Bernard,(unknown),Pierre‐François Laterre,E. Wesley Ely,(unknown),(unknown),(unknown),Jeffrey D. Helterbrand,(unknown),Gary Garber,Jean‐Louis Vincent	168
17	Prise en charge des hépatites fulminantes d'origine toxique en réanimation 2001 ·Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) ·Xavier Wittebole,Pierre‐François Laterre	1
18	An interim analysis of a phase II/III prospective randomized, multicenter, controlled trial of the HepatAssist (R) bioartificial liver support system for the treatment of fulminant hepatic failure. 2001 ·Hepatology ·A. Stevens,Jan Lerut,Pierre‐François Laterre	28
19	Baseline characteristics of patients enrolled in the phase III trial of rhAPC in severe sepsis 2000 ·Critical Care Medicine ·(unknown),(unknown),Rinaldo Bellomo,JA Russell,Pierre‐François Laterre,Antonio Artigas,(unknown),(unknown),Henrik Rieß,Julia Brown,E Knobel,GR Bernard	2
20	Transjugular Portosystemic Stent Shunting in Liver Transplanted Patients 1994 ·Hepatology ·Jan Lerut,Michel Mourad,Pierre Goffette,Pascal Bourlier,Pierre‐François Laterre,Jean-Bernard Otté	2

About Pierre‐François Laterre

Pierre‐François Laterre is a scholar working on Critical Care and Intensive Care Medicine, Epidemiology and Applied Microbiology and Biotechnology, having authored 182 papers that have together received 12.8k indexed citations. Recurring topics across this work include Sepsis Diagnosis and Treatment (61 papers), Intensive Care Unit Cognitive Disorders (23 papers) and Respiratory Support and Mechanisms (21 papers). The work is most often cited by research in Critical Care and Intensive Care Medicine (2.7k citations), Epidemiology (6.4k citations) and Applied Microbiology and Biotechnology (370 citations). Pierre‐François Laterre has collaborated with scholars based in Belgium, France and United States. Frequent co-authors include Jean‐Louis Vincent, Jean-François Dhainaut, E. Wesley Ely, Jeffrey D. Helterbrand, Charles J. Fisher, Xavier Wittebole, Thierry Dugernier, Howard Levy, Jean Roeseler and Konrad Reinhart. Their work appears in journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact